

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
19 September 2024 (19.09.2024)



(10) International Publication Number
WO 2024/189493 A1

(51) International Patent Classification:

A61K 31/428 (2006.01) C07D 417/14 (2006.01)
A61P 35/00 (2006.01) C07D 513/04 (2006.01)
C07D 417/12 (2006.01) C07D 519/00 (2006.01)

(21) International Application Number:

PCT/IB2024/052261

(22) International Filing Date:

08 March 2024 (08.03.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

2303582.7 10 March 2023 (10.03.2023) GB
2308738.0 12 June 2023 (12.06.2023) GB
2312354.0 11 August 2023 (11.08.2023) GB

(71) Applicant: **BREAKPOINT THERAPEUTICS GMBH**
[DE/DE]; Essener Bogen 7, 22419 Hamburg (DE).

(72) Inventors: **CORELLA, Andrea Guerrero**; c/o Evotec (UK) Ltd. Dorothy Crowfoot Hodgkin Campus, 114 Innovation Drive, Milton Park, Abingdon, Oxfordshire OX14 4RZ (GB). **FLANAGAN, Stuart Robert**; c/o Evotec (UK) Ltd. Dorothy Crowfoot Hodgkin Campus, 114 Innovation Drive, Milton Park, Abingdon, Oxfordshire OX14 4RZ (GB). **MALASSIS, Julien Gilbert Jacques**; c/o Evotec (France) SAS, Campus Curie 195, Route d'Espagne, 31036 Toulouse Cedex (FR). **HOLLICK, Jonathan**; c/o Breakpoint Therapeutics GmbH, Essener Bogen 7, 22419 Hamburg (DE). **SMITH, Matthew Raymond**; c/o Evotec (UK) Ltd. Dorothy Crowfoot Hodgkin Campus, 114 Innovation Drive, Milton Park, Abingdon, Oxfordshire OX14 4RZ (GB). **YULE, Ian Andrew**; c/o Evotec (UK) Ltd. Dorothy Crowfoot Hodgkin Campus, 114 Innovation Drive, Milton Park, Abingdon, Oxfordshire OX14 4RZ (GB). **BENTLEY, Jonathan, Mark**; Evotec (UK) Ltd. Dorothy Crowfoot Hodgkin Campus, 114 Innovation Drive, Milton Park, Abingdon, Oxfordshire OX14 4RZ (GB).

(74) Agent: **HGF LIMITED**; 1 City Walk, Leeds, West Yorkshire LS11 9DX (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available):

AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available):

ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

Published:

— with international search report (Art. 21(3))

(54) Title: INHIBITORS OF DNA POLYMERASE THETA



(57) Abstract: The present invention relates to compounds of the Formula I, and pharmaceutically salts thereof, wherein ring A, R₁, R₂, R₃, integer a, integer b, X₄, X₅, X₆ and X₇ are each as defined herein. The compounds of the present invention inhibit Polθ. The novel therapeutic compounds are therefore useful for the treatment and/or prevention of diseases and conditions in which Polθ activity is implicated, such as, for example but not limited to, the treatment and/or prevention of cancer. The present invention also relates to pharmaceutical compositions comprising the novel therapeutic compounds defined herein, to processes for synthesising these compounds and to their use for the treatment of diseases and/or conditions in which Polθ activity is implicated.

WO 2024/189493 A1